Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ocular side effects of bisphosphonates: A case report and literature review.

Literature DB >> 20944044

Ocular side effects of bisphosphonates: A case report and literature review.

Meredith McKague¹, Derek Jorgenson, Kelly A Buxton.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2010 PMID： 20944044 PMCID： PMC2954081

Source DB: PubMed Journal: Can Fam Physician ISSN： 0008-350X Impact factor: 3.275

× No keyword cloud information.

17 in total

1. Ocular inflammation associated with alendronate therapy.

Authors: J N Mbekeani; T L Slamovits; B H Schwartz; H L Sauer
Journal: Arch Ophthalmol Date: 1999-06

2. Bisphosphonates and ocular inflammation.

Authors: Frederick W Fraunfelder; Frederick T Fraunfelder
Journal: N Engl J Med Date: 2003-03-20 Impact factor: 91.245

3. Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy.

Authors: J M Durnian; A Olujohungbe; G Kyle
Journal: Eye (Lond) Date: 2005-02 Impact factor: 3.775

4. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects.

Authors: F W Fraunfelder; F T Fraunfelder
Journal: Ophthalmology Date: 2004-07 Impact factor: 12.079

Review 5. Red eye.

Authors: Sharon K Bal; Gary R Hollingworth
Journal: BMJ Date: 2005-08-20

6. Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.

Authors: Beate Aurich-Barrera; Lynda Wilton; Scott Harris; Saad A W Shakir
Journal: Drug Saf Date: 2006 Impact factor: 5.606

Review 7. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.

Authors: Ann Cranney; George Wells; Andrew Willan; Lauren Griffith; Nicole Zytaruk; Vivian Robinson; Dennis Black; Jonathan Adachi; Beverley Shea; Peter Tugwell; Gordon Guyatt
Journal: Endocr Rev Date: 2002-08 Impact factor: 19.871

8. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.

Authors: Ann Cranney; Gordon Guyatt; Lauren Griffith; George Wells; Peter Tugwell; Clifford Rosen
Journal: Endocr Rev Date: 2002-08 Impact factor: 19.871

Ocular side effects of bisphosphonates: A case report and literature review.

1. Ocular inflammation associated with alendronate therapy.

2. Bisphosphonates and ocular inflammation.

3. Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy.

4. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects.

Review 5. Red eye.

6. Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.

Review 7. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.

8. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.

Review 9. Ocular side effects associated with bisphosphonates.

10. Scleritis and other ocular side effects associated with pamidronate disodium.

Review 1. Ocular toxicity from systemically administered xenobiotics.

Review 2. Safety of long-term bisphosphonate therapy for the management of osteoporosis.

3. Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human cultured retinal pigment epithelial cells.

Review 4. Risedronate-associated scleritis: a case report and review of the literature.

5. Alendronate induced chorioretinitis: The importance of meticulous assessments.

6. Ocular Side Effects of Systemic Drugs Used in Dermatology.